secwatch.observer — SEC 8-K summary
======================================

Issuer:     Solid Biosciences Inc. (SLDB)
CIK:        0001707502
Form:       8-K
Filed at:   2022-09-30T23:59:59+00:00
Accession:  0001193125-22-254807
Event type: m_and_a
Sentiment:  neutral
Materiality: 0.80
Item codes: 1.01, 3.02, 5.02, 7.01, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Solid Biosciences acquires AavantiBio in stock deal, raises $75M PIPE, appoints new CEO
--------------------------------------------------------------------------------

- Acquires AavantiBio for 15% of SLDB common stock plus $1,000; AavantiBio lead program in Friedreich's Ataxia gene therapy.
- Concurrent $75M PIPE at $0.47/share; PIPE shares equal ~159.6M shares, closing after merger.
- Current CEO Ilan Ganot resigns effective closing; Alexander (Bo) Cumbo (AavantiBio CEO) to become new CEO; Adam Koppel joins board.
- Support agreements: 79% of AavantiBio and 29.8% of SLDB stockholders commit to vote in favor.
- Closing conditions include Nasdaq listing approval and stockholder approvals; termination fee $310k.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1707502/000119312522254807/0001193125-22-254807-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1707502/000119312522254807/d375823d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-22-254807

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer